Skip to Content Facebook Feature Image

Judiciary Commences Mandatory Use of iCMS for Civil Proceedings in High Court and District Court

HK

Judiciary Commences Mandatory Use of iCMS for Civil Proceedings in High Court and District Court
HK

HK

Judiciary Commences Mandatory Use of iCMS for Civil Proceedings in High Court and District Court

2026-11-20 15:40 Last Updated At:16:00

Judiciary commences mandatory use of iCMS for civil proceedings in High Court and District Court

The following is issued on behalf of the Judiciary:

The Judiciary announced today (November 20) the commencement of the mandatory use of the integrated Court Case Management System (iCMS) for civil proceedings in the High Court and the District Court following the promulgation of e-Practice Direction 5. The mandatory requirement will apply to the High Court from November 27, 2026, and the District Court from December 21, 2026.

The iCMS is an integral part of the Judiciary's Information Technology Strategy Plan. It aims to facilitate the electronic handling of court-related documents and payments across the various levels of court.

As set out in the new e-Practice Direction 5, the mandatory use of the iCMS applies to all legally represented parties and institutional parties (including mainly government bureaux and departments, law enforcement agencies and statutory bodies) involved in e-proceedings in respect of all the iCMS-enabled case types (Note 1).

Starting from the respective commencement dates, applicable users must use the e-system to commence a proceeding or file a document for the iCMS-enabled case types. Originating documents or other filings submitted in conventional (paper) mode and payments in such cases will no longer be accepted by the High Court and the District Court.

The mandatory use of the iCMS does not apply where the documents are exempted from the requirement, where permission has been given by the Court for using the conventional mode, and where a notice has been issued by the Judiciary for an unscheduled system outage or a technical problem which is not expected to be resolved within a reasonably short period ("Outage Notice") (Note 2). Furthermore, the mandatory requirement does not apply to proceedings or applications that are confidential in nature, including those relating to the Hong Kong National Security Law and the Safeguarding National Security Ordinance.

In exceptional cases, an applicable user may apply to a Practice Master of the High Court or District Court for permission to commence a proceeding or file a document in the conventional mode, explaining the details of the technical problems, special circumstances, or urgency involved. The Practice Master may grant permission only if good cause is shown and doing so is in the interest of justice.

Applicable users are reminded to ensure that e-filings are received by the Court within applicable time limits, taking into account factors such as system outage and other technical problems.

The e-Practice Direction 5, setting out its scope of application, exceptions and exemptions from mandated e-filing, and the procedures for consequential filing in the conventional mode, is accessible on the dedicated e-Courts webpage on the Judiciary website at www.judiciary.hk/en/e_courts/ref_practice.html.

The Judiciary. Photo source: reference image

The Judiciary. Photo source: reference image

For enquiries, please email enquiry@judiciary.hk, call the technical helpline at 2886 6474, or contact the respective court registry for enquiries on the progress of e-filing:

  • High Court Registry at 2825 0401

  • Clerk of Court's Office (Civil and Criminal Registry) at 2825 4672

  • Clerk of Court's Office (Appeals Registry) at 2825 4338

  • District Court Registry at 2582 4274

Note 1: The iCMS currently covers selected case types of civil proceedings of the High Court, including civil appeal cases in the Court of Appeal, and commercial, construction and arbitration, intellectual property, personal injuries and civil action cases in the Court of First Instance; personal injuries action, tax claim, civil action and employees' compensation cases in the District Court.

Note 2: Upon the issuance of an Outage Notice on the Judiciary's website, the mandatory e-filing requirement will be temporarily suspended. Users may then file documents in the conventional mode, accompanied by a valid Certificate of Outage downloaded from the website.

Hong Kong, China as regulatory member of International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use marks key step towards developing into international health and medical innovation hub

The Health Bureau announced today (November 20) that Hong Kong, China has formally joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) as a regulatory member. The ICH is a key international platform for the harmonisation of technical standards for drug regulation. Hong Kong's formal accession to ICH membership signifies international recognition of its drug research and development (R&D) as well as regulatory standards. It will help further promote the development of the capabilities and mechanisms for the "primary evaluation" of innovative drugs, enable Hong Kong to participate deeply in the formulation of international rules on drug R&D and registration, and accelerate the development of Hong Kong into an international health and medical innovation hub.

At its assembly meeting held in Czech Republic on November 17, 2026, the ICH approved the admission of Hong Kong, China (represented by the Pharmacy and Poisons Board of Hong Kong) as its 20th regulatory member. Other ICH regulatory members include the National Medical Products Administration of China and the regulatory authorities of Europe, Switzerland, the United Kingdom and the United States.

The Secretary for Health, Professor Lo Chung-mau, said, "The Hong Kong Special Administrative Region (HKSAR) Government expresses its sincere gratitude to the country for its continued full support for Hong Kong's development into an international health and medical innovation hub. Hong Kong, China becoming an ICH regulatory member fully demonstrates the unique advantages of the 'one country, two systems' principle. Since becoming an ICH observer on October 31, 2023, Hong Kong has, with the country's strong support, devoted its full efforts to fulfilling all the requirements of the ICH, and was able to formally become an ICH regulatory member in just three years, significantly accelerating the process compared with the eight to 10 years estimated by the Government earlier with reference to international experience."

Professor Lo added, "Looking ahead, the HKSAR Government will, in accordance with the First Five-Year Plan for Economic and Social Development of the Hong Kong Special Administrative Region (2026-2030), actively dovetail with the National 15th Five-Year Plan to support clinical R&D in biomedicine and optimise the evaluation and approval mechanism for innovative drugs, and drugs with urgent clinical use. The HKSAR Government will establish the Centre for Medical Products Regulation (CMPR) next month to build up capacity for independent drug evaluation and approval, and actively participate in international co-operation, with a view to developing Hong Kong into an international health and medical innovation hub and better integrating into and serving the overall national development."

The Director of Health, Dr Ronald Lam, said, "Joining the ICH marks an important milestone in Hong Kong's drug evaluation, approval and regulatory reform, and is particularly significant to the CMPR to be established soon. The CMPR will, in accordance with the technical requirements of the ICH, build up a professional team for independent evaluation and approval, enhance the efficiency of evaluating innovative drugs, and deploy experts to participate in the formulation and revision of ICH guidelines, contributing to the scientific advancement of drug regulation worldwide. Hong Kong is now both an ICH regulatory member and a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The CMPR will adopt a science-based approach and strive to become an internationally renowned regulatory authority."

The ICH is an authoritative international body for pharmaceutical harmonisation. The mission of the ICH is to harmonise global technical requirements for drug registration and to promulgate various guidelines on safety, efficacy and quality that are recognised as the highest international standards for the protection of public health. The PIC/S is a renowned international organisation comprising pharmaceutical regulatory authorities from multiple countries and regions. Its mission is to lead the international development, formulate standards for implementation, and adherence to harmonised Good Manufacturing Practice standards and quality systems among pharmaceutical regulatory authorities. Having passed the relevant assessment in 2015, Hong Kong, China formally became a PIC/S member with effect from January 1, 2016.

Source: AI-found images

Source: AI-found images

Recommended Articles